Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics, a leading ophthalmic gene therapy company that acquired UF startup AGTC to save and restore the vision of patients with blinding retinal diseases, announced it has raised $170 million in Series B funding.
Ascend Acquires Beacon Gene Therapy Manufacturing Site
Ascend Advanced Therapies, a gene therapy development partner, has purchased Beacon Therapeutics’ contract, manufacturing, and controls team—along with the company's site, previously owned by UF Innovate | Accelerate graduate AGTC, located in Alachua, FL—a town considered to be a “biotech hub” in the state. The acquisition introduces a good manufacturing practice (GMP) plant into the fold, along with process and analytical development capabilities.
